共 50 条
- [3] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors [J]. Rheumatology International, 2017, 37 : 2049 - 2058
- [5] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106
- [6] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence [J]. Rheumatology International, 2016, 36 : 987 - 995
- [9] Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD) [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2018, 10 : 151 - 160